Navigation Links
IDRI and Medicago to present data at the World Vaccine Congress
Date:4/9/2013

IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress. The meeting is being held at the Gaylord National Hotel and Convention Center in Washington, DC, April 16-18, 2013.

Dr. Steven Reed, Founder, President, & Chief Scientific Officer, IDRI, and Dr. Brian Ward, Professor of Medicine & Microbiology, McGill University, member of Medicago's scientific advisory committee, will be presenting at the World Vaccine Congress on April 17, 2013, at 2:35 p.m. EST. The presentation, titled "H5N1 Phase 1 clinical trial combining Medicago's VLP vaccine with IDRI's GLA adjuvant formulation," will discuss preliminary safety and immunology data from the ongoing H5N1 vaccine clinical trial.

The Phase I clinical trial, which commenced in September 2012, enrolled 100 healthy adult volunteers, aged 18-49 years, at three locations in the U.S., testing for safety and immune response. The vaccine was also tested in comparison to Medicago's H5N1 vaccine with alum. The trial is funded by a multi-million dollar grant IDRI received from the Defense Advanced Research Projects Agency (DARPA), a division of the United States Department of Defense, to investigate the safety and immunogenicity of a novel adjuvant with a Nicotiana benthamiana produced vaccine candidate. Each study participant in the trial received two doses of a given formulation in order to collect and compare data.

The trial focused on evaluating the safety and immunogenicity of the H5N1 vaccine, combined with IDRI's Glucopyranosyl Lipid A ("GLA") adjuvant, which was administered intramuscularly or intradermally. The intradermal route of administration was also tested in comparison with intramuscular delivery, using an FDA licensed device (MicronJet600, NanoPass Technologies) as the micro-needle device was previously shown in seasonal and pandemic flu tests to allow significant dose sparing. This study is among the first to test intradermal adjuvants.

"This trial is an important step toward development of an influenza vaccine that could be rapidly and widely administered in case of a pandemic outbreak," said Reed.

According to the Centers for Disease Control and Prevention, the highly pathogenic avian influenza A (H5N1) virus is a deadly virus that occurs mainly in birds including domestic poultry. Though relatively rare, sporadic human infections with this virus have occurred and caused serious illness and death. Because of the unpredictability of pandemic flu, efforts are being made to create and stockpile a vaccine to combat H5N1 that reduces the amount of vaccine needed per person and can be easily administered.

The H5N1 vaccine candidate includes IDRI's GLA adjuvant, which has been exclusively licensed to Immune Design Corp. for certain fields, including influenza, and is produced in Medicago's plant-based expression system, which is speedier than the traditional route of producing flu vaccines in eggs. The adjuvant system has been combined with Medicago's vaccine candidate and other recombinant protein antigens to elicit both humoral and cell-mediated immune responses associated with protection in pathogenic animal challenge models. In animal studies, GLA has also been shown to expand the cross reactivity of antibodies induced by the H5N1 vaccine to other potential pandemic influenza strains such as H2N2.


'/>"/>

Contact: Lee Schoentrup
lee.schoentrup@idri.org
206-518-6290
Infectious Disease Research Institute
Source:Eurekalert

Related medicine news :

1. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
2. Hollywood Star Tom Cruise Presented with Certificate of Irish Heritage
3. Body representation differs in children and adults
4. Career Step and MRA to Present on Assessing Coder Readiness at MaHIMA ICD-10 Summit
5. BeardedEagle Presents Pay It Forward Friday in Oklahoma City, OK
6. Live Continuing Medical Education Conference Hosted by Continuing Education Company Inc. Presents "What's Your Definition of Hypertension?" for Primary Care Physicians
7. Live Continuing Medical Education Conference hosted by Continuing Education Company presents Important Orthopedic Updates for Primary Care Physicians
8. Golden Tech's Greg Scasny to Present on "How to Build a Successful Business" at Greater Naples Chamber of Commerce on April 13th, 2003 9 am - 12 pm
9. Quorum Review IRB to Present “eConsent and the iPad: a Case Study” at Global ACRP Conference
10. Hooks Book Events and Sixth and I Present Paul Farmer with To Repair The World
11. Premium Astrology and Norah Guide Present Transition Period Guide To Luck and Happiness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: